{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:48:58Z","timestamp":1760885338158},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.mehy.2006.10.045","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T17:14:00Z","timestamp":1166030040000},"page":"199-202","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic possibilities of cysteamine in the treatment of schizophrenia"],"prefix":"10.1016","volume":"69","author":[{"given":"Chi-Un","family":"Pae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Ho","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2006.10.045_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0893-133X(97)00045-6","article-title":"Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity","volume":"17","author":"Lieberman","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.mehy.2006.10.045_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neures.2006.06.002","article-title":"Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines","volume":"56","author":"Nawa","year":"2006","journal-title":"Neurosci Res"},{"key":"10.1016\/j.mehy.2006.10.045_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","article-title":"The current status of the dopamine hypothesis of schizophrenia","volume":"1","author":"Carlsson","year":"1988","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.mehy.2006.10.045_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.31887\/DCNS.2006.8.1\/bsouza","article-title":"Dopaminergic intracellular signal integrating proteins: relevance to schizophrenia","volume":"8","author":"Souza","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.mehy.2006.10.045_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0278-5846(92)90071-L","article-title":"Plasmatic somatostatin as a marker of positive symptoms of schizophrenia","volume":"16","author":"Saiz-Ruiz","year":"1992","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1523\/JNEUROSCI.03-01-00232.1983","article-title":"Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei","volume":"3","author":"Chesselet","year":"1983","journal-title":"J Neurosci"},{"key":"10.1016\/j.mehy.2006.10.045_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neulet.2005.08.013","article-title":"Somatostatin modulates dopamine release in rat retina","volume":"391","author":"Kouvidi","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2006.10.045_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0006-3223(89)90196-0","article-title":"Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA","volume":"25","author":"Doran","year":"1989","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0091-3057(97)00020-8","article-title":"Cysteamine blocks amphetamine-induced deficits in sensorimotor gating","volume":"58","author":"Feifel","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.mehy.2006.10.045_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0143-4179(95)90018-7","article-title":"Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats","volume":"29","author":"Sakai","year":"1995","journal-title":"Neuropeptides"},{"key":"10.1016\/j.mehy.2006.10.045_bib11","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1523\/JNEUROSCI.16-14-04468.1996","article-title":"Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody","volume":"16","author":"Dournaud","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.mehy.2006.10.045_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0278-5846(90)90003-Y","article-title":"Preclinical and clinical studies with somatostatin related to the central nervous system","volume":"14","author":"Vecsei","year":"1990","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib13","first-page":"835","article-title":"Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system","volume":"14","author":"Vecsei","year":"1990","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1523\/JNEUROSCI.02-02-00225.1982","article-title":"Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine","volume":"2","author":"Sagar","year":"1982","journal-title":"J Neurosci"},{"key":"10.1016\/j.mehy.2006.10.045_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0006-8993(82)90660-6","article-title":"Selective depletion of somatostatin in rat brain by cysteamine","volume":"240","author":"Palkovits","year":"1982","journal-title":"Brain Res"},{"key":"10.1016\/j.mehy.2006.10.045_bib16","first-page":"140","article-title":"Comparative studies of intracerebroventricularly administered cysteamine and pantethine in different behavioral tests and on brain catecholamines in rats","volume":"305","author":"Vecsei","year":"1990","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.mehy.2006.10.045_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0167-0115(83)90006-X","article-title":"Inhibitory effects of cysteamine on neuroendocrine function","volume":"6","author":"Wehrenberg","year":"1983","journal-title":"Regul Pept"},{"key":"10.1016\/j.mehy.2006.10.045_bib18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/0091-3057(86)90509-5","article-title":"The effects of cysteamine on dopamine-mediated behaviors: evidence for dopamine-somatostatin interactions in the striatum","volume":"24","author":"Martin-Iverson","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.mehy.2006.10.045_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0166-4328(88)90065-4","article-title":"Intra-cerebral cysteamine infusions attenuate the motor response to dopaminergic agonists","volume":"29","author":"Lee","year":"1988","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.mehy.2006.10.045_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.npp.1300019","article-title":"Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release","volume":"28","author":"Balla","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.mehy.2006.10.045_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0893-133X(01)00230-5","article-title":"Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release","volume":"25","author":"Balla","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.mehy.2006.10.045_bib22","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0028-3908(99)00199-9","article-title":"Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304","volume":"39","author":"Kask","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mehy.2006.10.045_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00213-004-1782-1","article-title":"FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia","volume":"175","author":"Boeckler","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.mehy.2006.10.045_bib24","doi-asserted-by":"crossref","unstructured":"Minassian A, Feifel D, Perry W. The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients. Schizophr Res. 2006.","DOI":"10.1016\/j.schres.2006.08.006"},{"key":"10.1016\/j.mehy.2006.10.045_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.mp.4001637","article-title":"BDNF in schizophrenia, depression and corresponding animal models","volume":"10","author":"Angelucci","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0304-3940(01)02045-6","article-title":"Bromodeoxyuridine and methylazoxymethanol exposure during brain development affects behavior in rats: consideration for a role of nerve growth factor and brain derived neurotrophic factor","volume":"309","author":"Fiore","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2006.10.045_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0031-9384(00)00310-3","article-title":"Prenatal exposure to methylazoxymethanol acetate in the rat alters neurotrophin levels and behavior: considerations for neurodevelopmental diseases","volume":"71","author":"Fiore","year":"2000","journal-title":"Physiol Behav"},{"key":"10.1016\/j.mehy.2006.10.045_bib28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nn1730","article-title":"BDNF-mediated neurotransmission relies upon a myosin VI motor complex","volume":"9","author":"Yano","year":"2006","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.mehy.2006.10.045_bib29","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.biopsych.2005.01.010","article-title":"Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor","volume":"57","author":"Hill","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.4035-04.2005","article-title":"Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia","volume":"25","author":"Hashimoto","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.mehy.2006.10.045_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35075076","article-title":"BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization","volume":"411","author":"Guillin","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2006.10.045_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0278-5846(03)00112-X","article-title":"Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains","volume":"27","author":"Iritani","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.mp.4000718","article-title":"Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients","volume":"5","author":"Takahashi","year":"2000","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.mp.4001308","article-title":"Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia","volume":"8","author":"Weickert","year":"2003","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib35","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pages","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mehy.2006.10.045_bib36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1460-9568.2006.04686.x","article-title":"Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington\u2019s disease knock-in striatal cells","volume":"23","author":"Mao","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.mehy.2006.10.045_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","article-title":"Altered glutathione redox state in schizophrenia","volume":"22","author":"Yao","year":"2006","journal-title":"Dis Markers"},{"key":"10.1016\/j.mehy.2006.10.045_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.nbd.2006.01.003","article-title":"Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia","volume":"22","author":"Cabungcal","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.mehy.2006.10.045_bib39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0006-8993(87)90060-6","article-title":"Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry","volume":"403","author":"Haroutunian","year":"1987","journal-title":"Brain Res"},{"issue":"Suppl. 9","key":"10.1016\/j.mehy.2006.10.045_bib40","first-page":"9","article-title":"The neurobiology of cognition in schizophrenia","volume":"67","author":"Tamminga","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2006.10.045_bib41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0361-9230(86)90054-7","article-title":"Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists","volume":"16","author":"Hruska","year":"1986","journal-title":"Brain Res Bull"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987706007936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987706007936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T23:26:52Z","timestamp":1683674812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987706007936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0306987706007936"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2006.10.045","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}